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Abstract
Angiogenesis is critical in the development of cancer, which involves several angiogenic factors in its peritoneal
dissemination. The role of protein tumor progression locus 2 (Tpl2) in angiogenic factor–related endothelial cell
angiogenesis is still unclear. To understand the precise mechanism(s) of Tpl2 inhibition in endothelial cells, this
study investigated the role of Tpl2 in mediating angiogenic signals using in vitro, in vivo, and ex vivo models.
Results showed that inhibition of Tpl2 inhibitor significantly reduced peritoneal dissemination in a mouse model
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by positron emission tomography/computed tomography imaging. Simultaneously, inhibiting Tpl2 blocked
angiogenesis in tumor nodules and prevented angiogenic factor–induced proliferating cell nuclear antigen (PCNA)
in endothelial cells. Vascular endothelial growth factor (VEGF) or chemokine (C-X-C motif) ligand 1 (CXCL1)
increased Tpl2 kinase activity and phosphorylation in a dose- and time-dependent manner. Furthermore, Tpl2
inhibition or ablation by siRNA prevented the angiogenic signal–induced tube formation in Matrigel plug assay or
aortic ring assay. Inhibiting Tpl2 also prevented the angiogenic factor–induced chemotactic motility and migration
of endothelial cells. Tpl2 inhibition by CXCL1 or epidermal growth factor in endothelial cells was associated with
inactivation of CCAAT/enhancer binding protein β, nuclear factor κ light-chain enhancer of activated B cells, and
activating protein 1 and suppression of VEGF expression. Thus, Tpl2 inhibitors thwart Tpl2-regulated VEGF by inacti-
vating transcription factors involved in angiogenic factor–triggered endothelial cell angiogenesis. These results
suggest that the therapeutic inhibition of Tpl2 may extend beyond cancer and include the treatment of other diseases
involving pathologic angiogenesis.
Neoplasia (2013) 15, 1036–1048
Introduction
The serine-threonine protein kinase encoded by the tumor progres-
sion locus 2 (Tpl2) proto-oncogene, also known as Cot, is a mitogen-
activated protein kinase kinase kinase that is induced by Toll-like
receptor, pro-inflammatory cytokines like tumor necrosis factor, and
interleukin-1 in a variety of cell types [1–4]. Tpl2 is overexpressed in
different types of malignancies like large granular lymphocyte prolifer-
ative disorders and human breast cancer [5,6]. The overexpression of
Tpl2 in various cell types like colonic adenocarcinomas and gastric
adenocarcinomas [7,8] and the activation of different mitogen-activated
protein kinase pathways, nuclear factor–activated T cells, and nuclear
factor κ light-chain enhancer of activated B cells (NF-κB), as well as the
promotion of cell proliferation, have also been reported [2,3]. Previous
studies suggest that the proteinase-activated receptor-1–triggered acti-
vation of Tpl2 promotes actin cytoskeleton reorganization and cell
migration in stromal and tumor cells [9]. Suppressing Tpl2 diminishes
the growth of androgen depletion–independent prostate cancer [10].
Recently, Tpl2 has been reported as a key mediator of arsenite-induced
signal transduction of carcinogenesis in mouse epithelial cells [11].
Thus, Tpl2 is a critical component of the signaling pathway in tumor
cells. Endothelial cell function is essential to tumor angiogenesis and
peritoneal dissemination. However, the relevance of Tpl2 in angiogenic
factor–induced angiogenesis associated with endothelial cells and the
underlying mechanisms remain unclear.
Angiogenesis is critical in the development of cancer. The perito-
neal dissemination of cancer is a process that involves several angio-
genic factors, including vascular endothelial growth factor (VEGF),
epidermal growth factor (EGF), basic fibroblast growth factor
(bFGF), chemokine (C-X-C motif) ligand 1 (CXCL1), and other
critical factors [12–16]. Of the various manifestations of the cancer
progression, peritoneal dissemination is the most closely associated
with poor operative results [17–20]. Blocked angiogenesis in tumors
allows the anti-growth and anti-invasiveness of tumor cells leading to
prevent peritoneal dissemination [12,18]. VEGF-mediated angiogen-
esis is associated with enhanced endothelial cell survival and induc-
tion of neovascularization. Recent reports have shown that blood
vessels contain genetically normal and stable endothelial cells unlike
tumor cells, which typically display genetic instability and are cyto-
genetically abnormal, suggesting that the tumor microenvironment
contributes to these aberrations [21–23]. Therefore, anti-Tpl2 ther-
apy represents one of the most promising approaches to stop the
angiogenic process.
Several pathways have been involved in the angiogenesis induced
by angiogenic growth factors. Emerging evidence shows that tran-
scription factors are activated by phosphorylation and then trans-
located to the nucleolus that subsequently regulates angiogenesis [24].
Some of these [e.g., CCAAT/enhancer binding protein β (C/EBPβ),
NF-κB, activating protein 1 (AP1), hypoxia-inducible transcription
factor 1 alpha (HIF-1α), and specificity protein 1 (SP1)] bind to the
VEGF promoter to initiate and activate the transcription of a gene
directly. NF-κB is an important signal molecule associated with endo-
thelial cell survival andmigration induced by VEGF and bFGF [25–27].
A related activity factor C/EBPβ pathway activated by VEGF and
bFGF has also been implicated in the regulation of cell motility and
survival [28–30]. Specific knockdown of HIF-1α or Sp-1 in vitro leads
to reduced expression of both VEGF and CXCL1 [31–35]. As such,
the application of an anti-angiogenesis stratagem to control nuclear
factor activation may be a promising approach for regulating angio-
genesis, tumor growth, and metastasis. However, the molecular
mechanisms by which Tpl2 regulates endothelial cell migration and
tube formation are poorly understood.
The present study determined whether Tpl2 is necessary for endo-
thelial cell growth signal transduction by investigating the angiogenic
activities of Tpl2, including the promotion of a mouse model peri-
toneal dissemination in vivo, endothelial cell proliferation, migration
and capillary tube formation of human umbilical vein endothelial
cells (HUVECs) in vitro, and Matrigel plug assay in vivo. Because
the inhibition of Tpl2 prevented vessel sprouting in an aortic ring
assay ex vitro, the signaling pathways involved in angiogenesis medi-
ated by Tpl2 were also investigated. Lastly, the transcription factors
C/EBPβ, NF-κB, and AP1, the downstream effectors of Tpl2 for the
mediation of VEGF expression, were also analyzed.
Materials and Methods
Chemicals and Reagents
Lipofectin reagent was obtained from Invitrogen (Life Technologies,
Grand Island, NY). Specific Tpl2 inhibitor was purchased from
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Calbiochem (San Diego, CA; Cat. No. 616373) [10,11]. The [γ-32P]
adenosine triphosphate (ATP) was obtained from NEN (PerkinElmer,
Waltham, MA). Tpl2 siRNA and antibodies for Tpl2, Ki67, and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell Culture
HUVECs were obtained by collagenase treatment of umbilical cord
veins as described previously [36]. HUVECs from the third passage
were used, and the efficiency of transfection (>80%) by Lipofectin
reagent (Invitrogen) was determined at the third passage. In some
experiments, SV-40 immortalized mouse microvascular endothelial
cells (SVECs) were cultured in Dulbecco’s modified Eagle’s medium
Mixture F-12 supplemented with 10% FBS and 1% penicillin/
streptomycin/amphotericin B. The ethics review board of Taichung
Veterans General Hospital approved this study, which conforms to the
Declaration of Helsinki for use of human tissue (Approval Document
CE-12062).
Mouse Model of Animal Peritoneal Dissemination
All animal care and experimental procedures were approved and
conducted by the Committee for Animal Experiments of National
Chung Hsing University (Approval Document NCHU-100-26).
Four- to six-week-old male BALB/c nude mice were purchased from
National Laboratory Animal Center (NLAC; Taipei, Taiwan). The
mice were bred and maintained under specific pathogen-free condi-
tions, provided with sterilized food and water ad libitum, and housed
in a barrier facility with a 12-hour light/dark cycle.
Xenograft Tumor Mouse Model
In the peritoneal metastasis model, cultured human gastric cancer
cells (4 × 106 to 5 × 106 cells) were inoculated into the peritoneal
cavity of BALB/c nude mice. MKN45 and SCM-1, undifferentiated
adenocarcinoma cells, were obtained from the cell bank of Taipei
Veterans General Hospital (Taipei, Taiwan). Positron emission
tomography/computed tomography (PET/CT) was conducted 7 days
after the intraperitoneal inoculation to confirm where the tumor has
grown substantially in the abdominal cavity. If the tumor was success-
fully inoculated, the mice were injected intraperitoneally with Tpl2
inhibitor (2 mg/kg, twice per week). Serial surveillance PET/CT
images from 14, 28, and 49 days after treatment with Tpl2 inhibitor
were used to detect peritoneal dissemination. The mice were sacrificed
under anesthesia (pentobarbital) and examined macroscopically for
the presence of peritoneal metastasis. The tumors were excised, cut
into blocks, fixed in 10% formalin, and embedded in paraffin blocks
or snap-frozen in liquid nitrogen.
PET/CT Scanning
After at least 6 hours of fasting, the mice were given a 7.4-MBq
(0.2-mCi) dose of 18F-FDG orally before flushing with 1 ml of
water. The mice were anesthetized with an isoflurane vaporizer before
each scan. Experiments for small animal imaging were performed with
a combined PET/CT scanner (Discovery ST; GE Medical Systems,
Taichung, Taiwan). A multidetector row helical CT scanner was
used. Technical parameters used in the CT portion of PET/CT were
given as follows: CT scan type with a 0.5-second full helical scan;
detector row configuration, 1661.25 mm; interval space, 2.75 mm;
slice thickness, 1.25 mm; pitch, 1.75:1 (high-quality mode); speed,
17.5 mm per rotation; large field of view (FOV); voltage, 120 kVp;
current, 200 mA. Technical parameters used for the PET portion of
PET/CT included 10.0 minutes in each bed. The FOV chosen for
imaging reconstruction was 20 cm with PET resolution of about 4.5-mm
full width at half maximum. The reconstructive parameters were type
3D iteration as 21 subsets and two iterations. To evaluate the quan-
tification ability of the PET/CT scanner in small animal imaging, a
region of interest was placed on smaller FOV transaxial PET images
to completely surround the areas of FDG uptake in the observed tissues
while avoiding nearby tissues. The mean of each pixel’s activity value
within each region of interest was recorded and expressed as kBq/ml.
Immunohistochemistry
Assay was performed as previously described [18]. The expressions
of CD31 proteins in mouse solid tumors were examined by immuno-
histochemistry. All tumors were fixed in 10% buffered formalin
immediately after the animals were sacrificed. After pressure cooker
pretreatment in citrate buffer (pH 6.0) for 30 minutes, 5-μm sections
of the tumors were incubated at room temperature for 1 hour with a
monoclonal antibody for CD31 (1:500; Santa Cruz Biotechnology).
After incubation with an appropriate primary antibody enhancer, the
slides were incubated with HRP polymer (Laboratory Vision Corpo-
ration, Fremont, CA). Staining was evaluated by two independent
observers. For negative controls, primary antibodies were replaced
by phosphate-buffered saline (PBS). For quantization of mean vessel
density (MVD) in section, quantities were calculated as CD31-
positive area/total area. Reaction products were visualized by immers-
ing the slides in peroxidase-compatible chromogen. The slides were
counterstained with hemalaun.
Measurement of Cell Proliferation
Cell proliferation was measured using the CellTiter 96 AQueous
cell viability assay kit as described previously [37]. The assay was
composed of the tetrazolium compound 3,4-(5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt
(MTS) and an electron coupling reagent, phenazine methosulfate.
MTS was reduced by viable cells to formazan, which could be measured
with a spectrophotometer by the amount of 490-nm absorbance.
Cultures were seeded at 1 × 104 cells/well and allowed to attach over-
night. After incubation with the appropriate medium, 20 μl of MTS/
phenazine methosulfate mixture was added per well and the cells were
incubated for 1 hour before absorbance at 490 nmwas measured. Back-
ground absorbance from the control wells was subtracted. Four dupli-
cate studies were performed for each experimental condition.
Tpl2 Immunoprecipitation and Kinase Assay
The kinase activity was assessed as previously described with some
modifications [11]. Cells were cultured to 80% confluence and then
serum-starved in 0.1% FBS–minimum essential medium for 24 hours
at 37°C. The cells were treated with pro-angiogenic factors for dif-
ferent periods as indicated, disrupted with lysis buffer [20 mM
Tris-HCl (pH 7.4), 1 mM EDTA, 150 mM NaCl, 1 mM EGTA,
1% Triton X-100, 1 mM H-glycerophosphate, 1 mg/ml leupeptin,
1 mM Na3VO4, and 1 mM PMSF], and finally centrifuged at
20,000g for 10 minutes in a microcentrifuge. Lysates containing
500 to 1000 μg of protein were used for immunoprecipitation with
antibody against Tpl2 and then incubated at 4°C overnight. After the
addition of protein G Plus agarose beads, the mixture was continuously
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rotated at 4°C. The beads were washed three times with kinase
buffer [20 mM MOPS (pH 7.2), 25 mM H-glycerophosphate, 5 mM
EGTA, 1 mM Na3VO4, and 1 mM DTT], resuspended in 20 μl of
1× kinase buffer, and incubated for another 30 minutes at 30°C.
Then, 20 μg of myelin basic protein and 10 μl of diluted [γ-32P]
ATP solution were added, and the mixture was incubated for 10 min-
utes at 30°C. A 20-μl aliquot was transferred onto p81 paper and
washed three times with 0.75% phosphoric acid for 5 minutes per
wash, followed by a single wash with acetone for 2 minutes. The
radioactive incorporation was determined using a scintillation counter.
The experiments were done in triplicate.
Luciferase Reporter Assay
Endothelial cells at 60% confluence were co-transfected with 0.2 μg
of the promoter-reporter construct C/EBPβ, NF-κB, and AP1 and
0.1 μg of a thymidine kinase promoter–driven renilla-luciferase
vector (pRLTK; Promega, Mannheim, Germany). After 36 hours,
the cells were lysed and processed using the Dual Luciferase Kit
(Promega) as described by the manufacturer. Luciferase activity
was normalized to renilla firefly activity for transfection efficiency
and measured by a luminometer (LKB, Rockville, MD).
Tube Formation Assay
Assay was performed as previously described [18]. Matrigel was
thawed at 4°C overnight, and each well of prechilled 48-well plates
was coated with 100 μl of Matrigel and incubated at 37°C for 60 min-
utes. HUVECs (4 × 104 cells) were added to 1 ml of endothelial cell
growth medium (ECGM) with various concentrations of Tpl2 inhib-
itor. After 12 hours of incubation at 37°C and 5% CO2, endothelial
cell tube formation was assessed using a Nikon inverted microscope
with attached digital camera. Tubular structures were quantified by
manual counting under low-power fields, and the inhibition percent-
age was expressed using untreated wells as 100%.
Ex Vivo Vessel Sprouting Aortic Ring Assay
Assay was performed as previously described [18]. Aortas were iso-
lated from 6-week-old Sprague-Dawley rats. Plates (48-well) were
coated with 120 μl of Matrigel. Aortas isolated from mice were
cleaned of periadventitial fat and connective tissues and cut into 1- to
1.5-mm-long rings. After rinsing five times with endothelial cell–based
medium, the aortas were placed on the Matrigel-coated wells and
covered with another 100 μl of Matrigel. Tpl2 inhibitor or vehicle
was added to the wells in a final volume of 250 μl of medium. Cultures
were incubated, and media were replaced every second day over the
course of the 8 to 10 days of experiments. Visual counts of microvessel
outgrowths from replicate explant cultures (n = 4) were done under
bright-field microscopy following an established protocol. Experiments
were performed at least four times, andmicrovessel counts in treated and
control cultures were analyzed.
Endothelial Cell Migration Assay
The chemotactic motility of HUVECs was assayed using Transwell
(Corning Costar, Cambridge, MA) with 6.5-mm diameter poly-
carbonate filters (8-μm pore size) as described previously [18]. Briefly,
the lower surface of the filter was coated with 10 μg of gelatin type B.
Fresh M199 medium (1% FBS) containing VEGF was placed in the
lower wells. Cells were trypsinized and suspended in a final concen-
tration of 1 × 106 cells/ml in M199 containing 1% FBS. Various
concentrations of Tpl2 inhibitor were given to the cells for 60 minutes
at room temperature before seeding. One hundred microliters of the
cell suspension was loaded into each of the upper wells. The chamber
was incubated at 37°C for 4 hours. Cells were fixed and stained with
hematoxylin and eosin (H&E). Nonmigrating cells on the upper sur-
face of the filter were removed by wiping with a cotton swab. Chemo-
taxis was quantified by counting the cells that migrated to the lower
side of the filter with an optical microscope (×200). Ten fields were
counted for each assay. Monolayer-inactivated SVECs were wounded
by scratching with 1-ml pipette tip. Serum-free medium was added
with or without VEGF, bFGF, and CXCL1 (10 ng/ml) and different
concentrations of Tpl2 inhibitors. Images were taken by Nikon digital
camera after 4 to 8 hours. The migrated cells were quantified bymanual
counting, and the percentage inhibition was expressed using untreated
wells. At least four independent experiments were performed.
Matrigel Plug Model in Rats ( In Vivo Angiogenesis)
Nude mice or C57BL/6 mice were injected subcutaneously with
0.6 ml of Matrigel containing the indicated amount of VEGF or
CXCL1 (100 ng/0.6 ml) with or without Tpl2 inhibitor (50 μg/
0.6 ml). The injected Matrigel rapidly formed a single, solid gel plug.
After 30 days, the skin of the mouse was easily pulled back to expose
the Matrigel plug, which remained intact. Hemoglobin was mea-
sured using the Drabkin method and a Drabkin reagent kit 525
(Sigma, St Louis, MO) for the quantification of blood vessel formation.
Hemoglobin concentration was calculated from a known amount of
hemoglobin assayed in parallel. The images were photographed with
a Nikon digital camera, and the number of newly formed microvessels
was counted.
Immunoprecipitations and Western Blot Analysis
Proteins (80 μg) were separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis, electrophoretically transferred to
nitrocellulose membranes, and blocked for 1 hour in PBS containing
Tween 20 (0.1%) and nonfat milk (5%). Blots were incubated with
Tpl2, GAPDH, Ki67, and proliferating cell nuclear antigen (PCNA)
antibody (Santa Cruz Biotechnology) for 1 hour. Membranes were then
incubated for 1 hour with HRP-conjugated secondary antibody. After
further washing with PBS, the blots were incubated with commercial
chemiluminescence reagents (Amersham Biosciences, Piscataway, NJ).
The quantitative analysis of the protein expression was determined by
densitometry (Image-Pro Plus software).
VEGF Assay
VEGF concentrations were measured with a human VEGF ELISA
kit (R&D Systems, Minneapolis, MN).
Statistical Analysis
Values were presented as means ± SEM. Analysis of variance fol-
lowed by Fisher least significant difference test were performed for all
data. P < .05 was considered statistically significant.
Results
Tpl2 Inhibitor Diminished Peritoneal Dissemination
The maximum intensity projection of [18F]-FDG–PET/CT was
generated from typical representative mice (Figure 1A). Peritoneal
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dissemination was marked in the control mice (left panel), and it was
effectively reversed by the Tpl2 inhibitor treatment (right panel).
These images demonstrated that noninvasive [18F]-FDG uptake in
peritoneal dissemination of control mice was much higher than that
in the Tpl2 inhibitor–treated mice. In the quantification of intensity
(Figure 1B ), intraperitoneal injection of Tpl2 inhibitor significantly
reduced the estimated radioactivity counts and specific uptake values
(SUVs) determined by [18F]-FDG–PET/CT in mice inoculated with
gastric cancer cells. Moreover, by macroscopic image capture, the
control groups inoculated with MKN45 cells presented with many
metastatic nodules in the peritoneal cavity (mesentery; Figure 1C ).
In contrast, peritoneal tumor nodules were observed sporadically in
mice treated with Tpl2 inhibitor. The quantification of nodules per
field and tumor weight per mice was shown in Figure 1D. The
results indicated that Tpl2 inhibitor diminished the peritoneal dis-
semination of gastric tumor cells.
Inhibition of Tpl2 Reduced Tumor Angiogenesis and
Prevented HUVEC Proliferation
This study examined microvessel density in tumor in response to
Tpl2 inhibitor treatment in tissues using immunohistologic staining
of CD31 antibody. Tpl2 inhibitor significantly inhibited tumor angio-
Figure 1. Tpl2 inhibitor diminished peritoneal dissemination. [18F]-FDG–PET served as a representative estimate of therapeutic efficacy.
(A) Representative FDG–PET/CT images of animals inoculated with MKN45 gastric cancer cells with or without Tpl2 inhibitor treatment.
The maximum intensity projection of typical representative nude mice (left, tumor control; right, Tpl2 inhibitor treatment) showed many
metastatic nodules in the mesentery of the control mice inoculated with MKN45 cells. In contrast, peritoneal metastasis was observed
sporadically in Tpl2 inhibitor–treated mice. (B) Quantifications of estimated radioactivity (kBq/ml, left panel) and SUVs (right panel) were
calculated. SUV was used as an index to determine if a hot spot was significant. (C) Photomacrographs of metastatic peritoneal nodules
(arrows shown). (D) Quantifications of nodule number (left panel) and tumor weight (right panel). All data are presented as means ±
SEM (n = 6-8). *P < .05 compared to controls.
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genesis as indicated by reduced MVD in tumor mass (Figure 2A).
The hypothesis that Tpl2 inhibition could prevent angiogenesis was
also tested. Treatment of HUVECs with VEGF, bFGF, or CXCL1
for 24 hours significantly stimulated growth as determined by MTS
assay (Figure 2B ). This increase in growth was attenuated in the pres-
ence of Tpl2 inhibitor. In the absence of angiogenic factors, Tpl2
inhibitor alone did not affect the HUVEC growth. To exclude non-
specific effects of a pharmacological inhibitor, the Tpl2 message was
ablated by transient transfection of HUVECs with Tpl2 siRNA. Trans-
fection of HUVECs with Tpl2 siRNA, but not scrambled siRNA,
caused an 85% ablation of Tpl2 protein (Figure W1). Consistent with
previous data, transfection of HUVECs with Tpl2 siRNA significantly
inhibited VEGF- and bFGF-induced cell growth by 65% (Figure 2C ).
The inhibitory activity of Tpl2 inhibitor on VEGF-, bFGF-, or
CXCL1-induced HUVEC proliferation was also assessed by Western
blot analysis using antibody probe with PCNA and Ki67 (data not
shown), a proliferation marker. Treatment of HUVECs with VEGF,
bFGF, or CXCL1 increased PCNA expression, whereas Tpl2 inhibition
Figure 2. Tpl2 inhibitor reduced tumor angiogenesis and prevented angiogenic factor–induced proliferation of HUVECs. (A) Immunohis-
tochemistry of tumors stained with anti-CD31. Right panel: Quantitation of tumor vasculature indicated that Tpl2 inhibitor prevented
angiogenesis. The MVD of CD31 in each section was measured in five images from each treatment (n = 5). Bars, MVD in each treat-
ment; original magnification, ×100. (B) HUVECs were preincubated with Tpl2 inhibitor or (C) transfected with Tpl2 siRNA or scrambled
Tpl2 siRNA, followed by stimulation with VEGF, bFGF, or CXCL1. Cell viability was determined by MTS assay. All data are presented as
means ± SEM of five independent experiments. *P < .05 compared to controls.
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significantly prevented it. These results suggested that Tpl2 mediated
the VEGF-, bFGF-, or CXCL1-induced HUVEC growth.
Angiogenic Factor–Induced Phosphorylation and
Activation of Tpl2
To determine whether Tpl2 was involved in cellular response to
exposure to pro-angiogenic factors, the expression of Tpl2 induced
by pro-angiogenic factors in HUVECs and SVECs was examined.
VEGF, bFGF, or CXCL1 exposure caused a substantial elevation
of Tpl2 production (Figure 3, A and B) and kinase activity (Fig-
ure 3C ) in a time-dependent manner and induced the phosphory-
lation of Tpl2 in a dose-dependent manner (Figure 3D ). Exposure
to bFGF also showed a similar pattern (data not shown). VEGF or
CXCL1 induced phosphorylation of Tpl2 in a dose-dependent
manner. The level of phosphorylated Tpl2 or total Tpl2 protein was
determined by Western blot analysis. The relative value of density
for phosphorylation of Tpl2 bands was normalized to Tpl2, and this
was consistent with kinase activity of Tpl2 (data not shown). These
results indicated that VEGF or CXCL1 induced protein expression,
as well as the phosphorylation and kinase activity of Tpl2 in endo-
thelial cells.
Inhibition of Tpl2 Prevented Endothelial Cell
Tube Formation In Vitro
The effect of Tpl2 inhibition on tube formation induced by angio-
genic factors in HUVECs was examined. Inhibition by Tpl2 inhibitor
prevented angiogenic factors like VEGF-, bFGF-, and CXCL1-
induced (Figure 4, A–C ) endothelial cell tube formation in a
concentration-dependent manner. The endothelial cell tube forma-
tion by HUVECs was completely abolished at a higher concentration
(5 μM) of Tpl2 inhibitor. Consistent with data obtained with the
Tpl2 inhibitor, transfection of HUVECs with Tpl2-siRNA signifi-
cantly inhibited VEGF-, bFGF-, and CXCL1-induced tube forma-
tion by 75% (Figure W2). Scrambled RNA per se did not have any
effect. These results demonstrated that Tpl2 inhibition prevented
VEGF-, bFGF-, and CXCL1-induced angiogenesis in HUVECs.
Inhibition of Tpl2 Prevented Angiogenic Factor–Induced
Angiogenesis In Vivo
To determine whether Tpl2 inhibitor is capable of blocking
VEGF-induced angiogenesis in vivo, an established in vivo angio-
genesis model, the mouse Matrigel plug assay, was performed. Plugs
with VEGF or CXCL1 alone were markedly streaky, vascular, and
red. Plugs with Matrigel alone and containing VEGF and Tpl2 inhib-
itor or CXCL1 and Tpl2 inhibitor were pallid, indicating less blood
vessel formation (Figure 4, D and E ). Vessel density and vessel mor-
phology in the plug sections were also examined by H&E staining and
immunohistochemical staining with an antibody against CD31, an
endothelial cell marker. Vascularization in the Tpl2 inhibitor plus
VEGF or CXCL1 group was significantly reduced compared to that
in the VEGF alone group (Figure 4F ). Quantification of the vascu-
larization by counting the vessels (Figure 4G ) and endothelial cells
(Figure 4H ) revealed that the vascular density in the Tpl2 inhibitor–
treated group was significantly decreased. These indicated that the Tpl2
inhibitor was capable of inhibiting VEGF- or CXCL1-induced neo-
vessel formation in vivo.
Inhibition of Tpl2 Prevented Angiogenic Factor–Induced
Vessel Sprouting in an Aortic Ring Assay Ex Vitro
The sprouting of vessels from aortic rings was investigated to deter-
mine whether Tpl2 inhibitor blocked VEGF-induced angiogenesis
ex vivo. Extensive endothelial cell outgrowth from rat aorta ring
explants was observed in the control group (Figure 5A). Tpl2 inhib-
itor treatment resulted in a significant (about six-fold) reduction of
endothelial outgrowth and sprouting from aortic rings (Figure 5B),
suggesting that Tpl2 inhibition resulted in a significant reduction
in VEGF-induced vessel sprouting in a dose-dependent manner.
Inhibition of Tpl2 Prevented Angiogenic Factor–Induced
Chemotactic Motility and Migration of HUVECs and SVECs
The effects of Tpl2 inhibition on chemotactic motility of HUVECs
and SVECs were measured using either Transwell chamber assay or
wound scratch model assay. Tpl2 inhibition prevented the VEGF-
induced chemotactic motility of both HUVECs and SVECs in a
concentration-dependent manner (Figure 5, C and D). However,
Tpl2 inhibition alone had no significant effect on basal migration of
endothelial cells. The effect of Tpl2 inhibition on VEGF-induced
Figure 3. Angiogenic factor–induced phosphorylation and activa-
tion of Tpl2. VEGF or CXCL1 induced the phosphorylation of
Tpl2 in a time- and dose-dependent manner. (A) Cells were ex-
posed to VEGF or (B) CXCL1 and harvested at the indicated time.
Levels of Tpl2 or GAPDH proteins were determined by Western
blot analysis at the indicated concentration. (C) VEGF or CXCL1 in-
duced Tpl2 kinase activity in a time-course response. (D) VEGF or
CXCL1 induced Tpl2 kinase activity in a dose-dependent manner.
Cells were disrupted and kinase activity of Tpl2 was determined as
described in the Materials and Methods section. All data are pres-
ented as means ± SEM of five independent experiments. *P< .05
compared to controls.
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migration of HUVECs and SVECs was determined using the wound
scratch model assay (Figure 5, E and F ). Inhibition of Tpl2 by phar-
macological inhibitor or ablation of Tpl2 using specific siRNA
significantly prevented endothelial cell migration. Thus, Tpl2 inhibi-
tion prevented the invasion and migration of endothelial cells.
Constraint of Tpl2 Blocks C/EBPβ, NF-κB,
and AP1 Activation
The VEGF gene contained C/EBPβ, NF-κB, and AP1 binding
sites within its promoter, thereby activating transcription and gene
expression. To determine the transcriptional activity and VEGF
expression of endothelial cells in response to CXCL1 and EGF,
the expression of transcriptional activity was measured by luciferase
reporter assay. Cells pretreated with Tpl2 inhibitor markedly inhibited
CXCL1- or EGF-induced C/EBPβ, NF-κB, and AP1 activation. A
Tpl2 siRNA was transfected into SVECs, which were then trans-
fected with a C/EBPβ, NF-κB, and AP1 luciferase plasmid. CXCL1
or EGF treatment decreased C/EBPβ, NF-κB, and AP1-dependent
transcriptional activity in Tpl2 siRNA cells compared to control
scrambled RNA cells (Figure 6, A–C ). These data showed that
Figure 4. Inhibition of Tpl2 prevented angiogenic factor–induced endothelial cell tube formation in vitro and in vivo Matrigel plug assay.
Tpl2 inhibitor or Tpl2 siRNA suppressed the endothelial cell tube formation. HUVECs preincubated with Tpl2 inhibitor or transfected with
Tpl2 siRNA or scrambled Tpl2 siRNA were stimulated with (A) VEGF, (B) bFGF, or (C) CXCL1. Tube formation images were captured in an
inverted photomicroscope (left panel), and tube formations were scored. For the in vivo Matrigel plug assay, (D) and (E) represented
Matrigel plugs and (F) represented H&E staining of sections fromMatrigel plugs. (G) Quantifications of vessel numbers and (H) endothelial
cells in Matrigel plug sections (counts/field) were calculated. The numbers in each case were the average of five different slides and five
regions per slide. All data are presented as means ± SEM of three independent experiments (n = 3). *P < .05 compared to controls.
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C/EBPβ, NF-κB, and AP1 were downstream regulators of Tpl2 for
CXCL1- or EGF-induced VEGF expression. In addition, transfection
of Tpl2 siRNA into cells also inhibited the generation of VEGF
(Figure 6D). The combination of Tpl2 inhibitor with CXCL1 or
EGF in cells also markedly reduced VEGF production when compared
to either treatment alone. These results indicated that Tpl2 was a
potent anti-angiogenic molecule.
Discussion
A major form of tumor recurrence is peritoneal dissemination, and a
crucial problem in such tumor growths is tumor angiogenesis [38–41].
Angiogenesis plays a critical role in the fundamental physiologic process
and pathologic neovascularization. Solid tumors in the early stage
secrete VEGF and other pro-angiogenic factors to evoke tumor angio-
genesis [42,43]. The main signaling circuit of VEGF is thought to
Figure 5. Inhibition of Tpl2 prevented angiogenic factor–induced vessel sprouting in an aortic ring assay ex vitro, chemotactic motility, and
migration of HUVECs and SVECs. (A) Tpl2 inhibitor inhibited endothelial cell sprouting in an aortic ring assay. (B) The endothelial cell
sprouting was abundant in the control aortic rings but not in the rings treated with Tpl2 inhibitor. (C) HUVECs or (D) SVECswere pretreated
with various concentrations of Tpl2 inhibitor before VEGF treatment. After incubation, chemotaxis was quantified by counting the cells
that migrated to the lower side of the filter with optical microscopy at ×200 magnification. The basal migration in the absence of VEGF
was 100 ± 10 cells/field. (E) Tpl2 inhibitor inhibited SVECmigration. Cells migrating into the wound area were counted on the basis of the
dash line. The representative photographs showed the same area at 12 hours with VEGF, bFGF, and CXCL1 and before preincubation with
or without Tpl2 inhibitor. (F) These results were representative of four independent experiments. *P < .05 compared to controls.
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involve activation of transcription factors, which are implicated in all
critical endothelial functions, including proliferation, migration, and
angiogenesis. Other potent pro-angiogenic factors like EGF, bFGF,
and CXCL1 evoke vast amount of transcription factors that can trigger
a signaling pathway involved in the growth of endothelial cells [44–46].
The results suggest that Tpl2 is upstream of the transcription factors.
More importantly, the findings here reveal for the first time that Tpl2-
mediated angiogenesis is characteristic of endothelial cells in vitro,
in vivo, and ex vivo, indicating a novel anti-angiogenic function of
Tpl2 inhibitors that control transcription factors.
Many transcription factors have been shown to regulate VEGF in
response to angiogenesis, including NF-κB, C/EBPβ, AP1, SP-1,
STAT-3, and HIF-1α [18,27,31,47]. However, although factors relay
available pro-angiogenic factors to functional endothelial cells, none
of them accounts for the actual targeting of Tpl2. Proto-oncogene
Tpl2 is a serine-threonine kinase that integrates signals from Toll
receptors, cytokine receptors, progression of rodent T cell lympho-
mas, and T cell activation [5,48,49]. Overexpression of Tpl2 has been
found in breast cancer, gastric cancer, and colon adenocarcinoma
[6–8]. Paradoxically, loss of Tpl2 enhances tumorigenesis and inflam-
mation in two-stage skin carcinogenesis, indicating that Tpl2 may serve
more as a tumor suppressor than as an oncogene in chemically induced
skin carcinogenesis, its absence contributing to both tumorigenesis
and inflammation [50]. Interestingly, Tpl2 ablation promotes intes-
tinal inflammation and tumorigenesis in Apcmin mice by inhibiting
interleukin-10 secretion and regulatory T cell generation, suggesting
that Tpl2 also has a critical role in regulating systemic inflammation
and in the susceptibility to intestinal tumorigenesis [51]. Tpl2 knock-
out mice are resistant to lipopolysaccharide (LPS)/D-galactosamine–in-
duced pathology, because of the low production of tumor necrosis
factor–α among other cytokines, implying that endogenous Tpl2 may
be involved in innate and adaptive immunity rather in proliferative
signals physiologically [52]. Although previous studies suggest that
Tpl2 possesses different functions, the role of Tpl2 in endothelial cells
and in regulating angiogenesis remains poorly understood. The present
study shows that Tpl2 inhibitor markedly diminishes tumor peritoneal
dissemination and reduces tumor angiogenesis in amouse model. Other
evidence demonstrates that Tpl2 inhibitor causes tumor burden changes
and inhibits tumor growth within 2 weeks. These changes are consistent
with the results of PET/CT imaging studies and nodule counts in the
present study. Therefore, constitutively high levels of Tpl2 activity may
disturb cell regulation and lead to abnormal functioning in cells.
Previous reports have shown that transcription factors are over-
active in most human cancer cells and are thus suitable potential tar-
gets for the development of anticancer drugs. Darnell et al. reported
that to be considered an ideal target for cancer therapy, a transcrip-
tion factor needs to fulfill four main criteria [24]. However, in spite
of an ever-increasing number of putative small molecule inhibitors of
transcription factors, only a handful are currently progressing
through preclinical and early clinical development. Cytoplasmic pro-
teins activate transcription factors further, then relay the signal into
the nucleus and change the transcription pattern of the cell, with the
ultimate outcome of upregulating or downregulating gene expres-
sion. Thus, targeted disruption of Tpl2 in the endothelial cell growth
to decrease angiogenesis and peritoneal dissemination is a promis-
ing strategy. Tpl2 is reported to be capable of activating both the
mitogen-activated protein kinase and c-jun-N-terminal kinase
( JNK) kinase pathways. In addition, the Tpl2 kinase can activate
transcription factors such as inhibitor of NFκB (IκB) kinases and
can induce the nuclear production of NF-κB [53]. Li et al. have
shown that the Tpl2/AP1 signaling transduction pathway is a posi-
tive regulator of MHV-68 lytic replication [54]. However, in the
present study, an inhibitor of Tpl2 comprehensively blocks C/EBPβ,
NF-κB, and AP1 activation in pro-angiogenic factor–induced activation
Figure 6. Constraint of Tpl2 blocked C/EBPβ, NF-κB, and AP1 acti-
vation. Tpl2 inhibitor or Tpl2 siRNA inhibited VEGF-, bFGF-, and
CXCL1-induced C/EBPβ, NF-κB, and AP1 promoter activity. Endo-
thelial cells (SVECs) that were transiently transfected with the (A)
C/EBPβ, (B) NF-κB, and (C) AP1 luciferase reporter plasmid and a
thymidine kinase promoter–driven Renilla-luciferase vector were
transiently transfected with Tpl2 siRNA or control scrambled
RNA and treated with VEGF, bFGF, and CXCL1. The relative activity
was measured by luciferase assay as described in the Materials
and Methods section. Means ± SEM of luciferase activities were
calculated from triplicate determinations. (D) Tpl2 inhibitor or Tpl2
siRNA reduced VEGF-, bFGF-, and CXCL1-induced VEGF secretion.
VEGF generation was determined using the VEGF ELISA kit as
described in the Materials and Methods section. All data were
presented in four determinations. *P < .01, for significant differ-
ence between groups.
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of endothelial cells. Simultaneously, Tpl2 inhibition can block
cancer cell survival, proliferation, and tumor growth reduction in an
animal study (data not shown). These findings suggest that
regulating the function of Tpl2 and the subsequent control of
transcription factor activity may provide a new therapeutic strategy
against pathologic diseases. Moreover, circulating VEGF seems to be
a reliable surrogate marker of angiogenic activity and tumor progression
in cancer patients. On the basis of these observations, targeting
the VEGF signaling cascade may be a useful component of an anti-
angiogenic strategy. The results here demonstrate that the addition of
Tpl2 inhibitors significantly reduces CXCL1- or bFGF-induced VEGF
production, which may provide insights into potential strategies for
preventing the development of angiogenesis and metastasis. This also
opens a potential role of anti-angiogenic therapy in suppressing the
development of metastases after cancer resection. The candidate gene
Tpl2 appears to exhibit the most direct action and may therefore have
the potential as a target for cancer treatment.
Vascular endothelial cells respond to alarm signals of the body by
angiogenesis or inflammation [55]. Inflammatory tissue is often hyp-
oxic, which can induce angiogenesis through the up-regulation of
factors such as VEGF [56]. Moreover, a previous report shows that
VEGF-A induces the recruitment of leukocytes to the inflamed
intestine in vivo, thus fostering inflammation. These strongly support
the important role played by the VEGF pathway in both inflamma-
tion and angiogenesis underlying disease pathogenesis in inflamma-
tory bowel disease (IBD) [57]. There is considerable evidence to
suggest that angiogenesis and chronic inflammation are co-dependent.
Conversely, inhibition of angiogenesis is predicted to diminish chronic
inflammatory responses and several examples of this have been observed
[56,58]. In the present work, angiogenic factors VEGF, CXCL1, and
bFGF have markedly induced Tpl2 activation and endothelial cell pro-
liferation. Tpl2 inhibitors effectively reverse angiogenesis in activated
endothelial cells. Thus, it can be considered that Tpl2 inhibitors, spe-
cifically inhibitors of angiogenesis, are new targets, and the intriguing
connection between angiogenesis and inflammation can be further
explored. Pharmacologic control of angiogenesismay hold great promise
for the alleviation of inflammatory states.
Angiogenesis and lymphogenesis are commonly seen in tumor
masses, especially at the tumor margins. Detection of MVD and lym-
phatic vessel density (LVD) at tumor borders may be useful in predict-
ing metastasis and in prognosticating in patients with a tumor mass. In
particular, co-accounting ofMVD and LVDmay be a useful prognostic
factor in tumor masses. Lymphatic endothelial cell marker hyaluronan
receptor LYVE-1 and CD31, also known as platelet endothelial cell
adhesion molecule 1, are used primarily to demonstrate the presence
of endothelial cells in histologic tissue sections [59–62]. These markers
can help evaluate the degree of extension and growth of tumor endo-
thelial cells, which can indicate a rapidly growing tumor. Malignant
endothelial cells also commonly retain the antigens, so CD31 and
LYVE-1. Immunohistochemistry may be used to demonstrate their
presence. In addition, the aforementioned finding has been proven in
animal models and clinicopathologic studies [59–62]. Emerging evi-
dence show that vascular targeting agents are aimed specifically at the
existing tumor vasculature. Anti-angiogenic agents target angiogenesis
or the new growth of tumor vessels. The present study uses primary
HUVECs, which are cells derived from the endothelium of veins from
the umbilical cord, for angiogenesis. Moreover, mouse lymphoid micro-
vascular endothelial immortalized cell line (SVEC) can indicate the
probable therapeutic efficacy in lymphogenesis. The inhibition of
Tpl2 can prevent in vivo, in vitro, and ex vivo angiogenesis in a mouse
model. Angiogenesis and lymphogenesis, which are dependent on endo-
thelial cells, are important in the growth and metastasis of solid tumors
and are regulated by Tpl2 activation. For the first time, the present study
shows that Tpl2 is an excellent novel therapeutic target for the preven-
tion of angiogenesis and suggests that it may be a highly promising strat-
agem for lymphogenesis therapy in the future.
In conclusion, the inhibition of Tpl2 prevents angiogenesis in vivo,
in vitro, and ex vivo. Tpl2 inhibition diminishes peritoneal dissemi-
nation and tumor angiogenesis. The Tpl2-mediated inhibition of
peritoneal endothelial cell growth, chemotactic motility, and migra-
tion is associated with blockade of pro-angiogenic growth factor–
induced transcription factor activity and the down-regulation of VEGF
expression. There is a novel role of Tpl2 in regulating the angiogenic
process and inhibiting it may prevent cancer growth and peritoneal dis-
semination by ameliorating angiogenesis. Hence, Tpl2 inhibitors can
lead to the development of pharmaceutical drugs for the treatment of
angiogenesis-dependent human diseases like tumors.
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Figure W1. Tpl2 siRNA transfection efficacy detected by Western
blot analysis. The efficiency of transfection by Lipofectin reagent
(Invitrogen) was determined on the third passage. Transfection of
HUVECs with Tpl2 siRNA but not scrambled siRNA caused 85%
ablation of Tpl2 protein. Quantification of the protein expression
was performed by densitometric analysis (Image-Pro Plus software).
Figure W2. Quantification of HUVEC tube formation.
